AlloSure Lung Assessment and Metagenomics Outcomes Study

Description

ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).

Conditions

Lung Transplant Infection, Lung Transplant; Complications, Lung Transplant Failure and Rejection

Talk to us

Study Overview

On this page

Study Details

Study overview

ALAMO is a prospective, multi-center, perspective, registry of patients receiving LungCare™ (AlloSure®-Lung, AlloMap Lung, and HistoMap) for surveillance post-transplant. This study aims to evaluate the diagnostic performance characteristics of AlloSure Lung (dd-cfDNA) to detect a spectrum of rejection (ACR, AMR) and allograft infection (Bacterial, Viral, Fungal, Mycobacterial, Parasitic).

AlloSure Lung Assessment and Metagenomics Outcomes Study

AlloSure Lung Assessment and Metagenomics Outcomes Study

Condition
Lung Transplant Infection
Intervention / Treatment

-

Contacts and Locations

Birmingham

University of Alabama (UAB), Birmingham, Alabama, United States, 35233

Phoenix

St. Joseph's Hospital & Medical Center, Phoenix, Arizona, United States, 85013

Los Angeles

Cedars Sinai Medical Center, Los Angeles, California, United States, 90048

San Francisco

University of California (UCSF) School of Medicine, San Francisco, California, United States, 94143

Aurora

University of CO Anschutz Medical Campus, Aurora, Colorado, United States, 80045

Orlando

AdventHealth Orlando, Orlando, Florida, United States, 32804

Maywood

Loyola University Medical School, Maywood, Illinois, United States, 60153

Louisville

University of Louisville Health, Louisville, Kentucky, United States, 40202

Baltimore

University of Mayland, Baltimore, Maryland, United States, 21201

Boston

Brigham and Womens Hospital, Boston, Massachusetts, United States, 02115

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Unilateral or Bilateral, deceased-donor, initial or re-transplant
  • 2. ≤ 90 days post-transplant
  • 3. Ability to understand and provide informed consent and adhere to laboratory surveillance schedule
  • 4. Patients who have LungCare initiated within 30 days of signing the informed consent form
  • 1. Multi-organ transplants
  • 2. Pregnancy
  • 3. Active malignancy

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

CareDx,

Debbie Levine, PRINCIPAL_INVESTIGATOR, Stanford University

Nirmal Sharma, PRINCIPAL_INVESTIGATOR, Brigham and Women's Hospital

Study Record Dates

2028-12-31